CXCL9、GBP5和IFNG的表达谱是预测免疫治疗反应的一种潜在的泛癌生物标志物。
The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response.
作者信息
Wang Jingpu, Zhou Yuan, Yang Yang, Wu Zhouqiao
机构信息
Department of Surgery, University Medical Center Utrecht Utrecht, The Netherlands.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute Beijing, China.
出版信息
Am J Transl Res. 2023 Jun 15;15(6):3960-3975. eCollection 2023.
BACKGROUND
The effectiveness of immunotherapy has been validated in multiple cancers. However, not all patients benefit from immunotherapy, and its objective response rate is less than 30% in some cancers, so it is of great importance to find a pan-cancer biomarker that can effectively predict immunotherapy response.
METHODS
Fifteen immunotherapy datasets were retrospectively analyzed to determine pan-cancer biomarkers to predict immunotherapy response. A total of 348 patients with metastatic urothelial carcinoma (mUC) who received anti-PD-L1 immunotherapy from the dataset of IMvigor210 trial were included in the primary analysis. In addition, 12 public immunotherapy datasets of different cancers and two datasets of gastrointestinal cancer patients who received anti-PD-1 or anti-PD-L1 immunotherapy between August 2015 and May 2019 at Peking University Cancer Hospital (PUCH) were analyzed as validation cohorts.
RESULTS
The expression of CXCL9, IFNG, and GBP5 was independently associated with the response to anti-PD-L1 immunotherapy in patients with mUC. The ability of the expression panel of CXCL9, IFNG, and GBP5 to predict immunotherapy response was validated in immunotherapy datasets of different cancers.
CONCLUSION
The expression panel of CXCL9, IFNG, and GBP5 can potentially be a pan-cancer biomarker for predicting immunotherapy response.
背景
免疫疗法的有效性已在多种癌症中得到验证。然而，并非所有患者都能从免疫疗法中获益，并且在某些癌症中其客观缓解率低于30%，因此找到一种能够有效预测免疫疗法反应的泛癌生物标志物非常重要。
方法
回顾性分析15个免疫疗法数据集，以确定预测免疫疗法反应的泛癌生物标志物。IMvigor210试验数据集中共有348例接受抗PD-L1免疫疗法的转移性尿路上皮癌（mUC）患者纳入主要分析。此外，分析了12个不同癌症的公共免疫疗法数据集以及2015年8月至2019年5月期间在北京大学肿瘤医院（PUCH）接受抗PD-1或抗PD-L1免疫疗法的胃肠道癌患者的两个数据集作为验证队列。
结果
CXCL9、IFNG和GBP5的表达与mUC患者抗PD-L1免疫疗法的反应独立相关。CXCL9、IFNG和GBP5表达组预测免疫疗法反应的能力在不同癌症的免疫疗法数据集中得到验证。
结论
CXCL9、IFNG和GBP5表达组可能是预测免疫疗法反应的泛癌生物标志物。
Zotero 插件